01—Abstract
Summary
Summary of the 10-K filed March 19, 1998. Cited figures are marked; the original filing is the authoritative source.
Important: the filing provided is Schering-Plough Corporation's Form 10-K for fiscal year 1997, not Merck & Co.'s (MRK) filing, so this analysis covers Schering-Plough (NYSE: SGP).
Schering-Plough had a strong 1997. Sales rose 20% to $6.78 billiona, driven mainly by volume growth of 20%, with worldwide CLARITIN sales reaching $1.7 billion (up from $1.2 billion). Income from continuing operations grew 19% to $1.44 billion, and diluted EPS rose 20% to $1.95.
The company's 24.5% effective tax rate was unchanged, and the June 1997 purchase of Mallinckrodt's animal health business added about $171 millionb of 1997 sales. Management also cut the debt-to-total-capital ratio to 18% from 30%, while returning capital through a $542 million dividend and $132 million of share repurchases. The main investor questions center on concentration and litigation.
CLARITIN is the dominant growth driver, and in February 1998 generic maker Geneva filed an ANDA seeking to market a generic Claritin several years before patent expiration. Schering-Plough sued in March 1998, and management believes it should prevail, but it gave no assurance of that. The company also faces more than 160 antitrust actions over prescription drug pricing, an FTC price-fixing investigation, a Foxmeyer-related suit seeking $400 millionc, and 185 lawsuits involving more than $2 billion in claimed damages tied to synthetic estrogens (DES).
Management considers material liability beyond amounts accrued to be remote in most cases. Operating investments are rising. R&D spending reached $847 milliond, about 12.5% of sales, and SG&A rose to 39.3% of sales as the company expanded its field force and promotion.
Capital expenditures were $373 million, with about $490 million planned for 1998. Year 2000 remediation is estimated at about $50 million, with completion expected by year-end 1998. Foreign sales were about 40% of the total, and no single foreign country exceeded 5% of consolidated sales.
02—Key points
Key Highlights
- Sales grew 20% to $6,778 million in 1997 (1996: $5,656 million), with volume up 20% and price up 3%, partly offset by a 3% foreign exchange headwind.
- Net income rose 19% to $1,444 million; diluted EPS was $1.95, up 20% from $1.63, supported by share repurchases and a 24.5% effective tax rate.
- CLARITIN was the key growth driver, with worldwide sales of $1.7 billion versus $1.2 billion in 1996; the Geneva ANDA challenge and related patent litigation make it a key risk.
- R&D expense rose 17% to $847 million (about 12.5% of sales), and SG&A rose 21% to $2,664 million (39.3% of sales), reflecting higher promotional spending.
- The June 1997 Mallinckrodt animal health acquisition (about $490 million including assumed debt) boosted animal health sales 103% to $389 million.
- The balance sheet strengthened: the debt-to-total-capital ratio fell to 18% from 30%, shareholders' equity rose to $2,821 million, and a new $1 billion buyback began in January 1998.
- Litigation exposure is significant, including more than 160 antitrust actions, an FTC price-fixing investigation, and DES-related suits claiming over $2 billion, though management considers material excess liability remote.
03—Questions
Frequently Asked Questions
How dependent is Schering-Plough's growth on CLARITIN?
Highly dependent. CLARITIN sales of $1.7 billion accounted for roughly a quarter of 1997 sales of $6.78 billion, and it drove much of the allergy/respiratory segment's 33% domestic growth to $2.7 billion. Any loss of exclusivity or generic entry would materially affect revenue and earnings.
What is the status of the Geneva generic Claritin challenge?
Geneva Pharmaceuticals filed an ANDA in February 1998 seeking to market a generic Claritin several years before the Company's patents expire and alleging certain U.S. Claritin patents are invalid. Schering-Plough filed suit in March 1998 claiming willful infringement and believes it should prevail, but the filing notes no assurance of outcome.
How much did the Mallinckrodt animal health acquisition contribute, and what did it cost?
The company bought Mallinckrodt's worldwide animal health operations in June 1997. The filing cites a cost of about $490 million including assumed debt and direct costs, and about $354 million in cash in the MD&A. Mallinckrodt contributed about $171 million to 1997 animal health sales, and the company says the deal created a world-class animal health business.
Could pending litigation materially hurt the company's finances?
Management says it is remote that material liability beyond accrued amounts will result from the DES suits (claimed damages over $2 billion), the antitrust actions, and the Superfund matters. However, the FTC price-fixing investigation is ongoing and the Foxmeyer suit seeks $400 million, so outcomes are uncertain and the filing offers no precise estimate.
04—Continue